Efficacy of hemoglobin A1C (HbA1C) achievement between insulin based therapy and dual oral hypoglycemic agents in newly diagnosed type 2 diabetes patients with very high hemoglobin A1C

• Conditions: newly diagnosed type 2 diabetes patients; hemoglobin A1C insulin based therapy dual oral hypoglycemic diabetes patients

• Registration Number: TCTR20220210005
• Lead Sponsor: ampang hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-02-10
• Study Completion: 2023-05-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: nknown
• Sex: All
• Target Recruitment: 76

Inclusion Criteria

1.newly diagnosed type 2 diabetes patients 2.patients with very high hemoglobin A1C (greater than or equal to nine percent) 3.patients with eGFR greater than or equal 45 m

Exclusion Criteria

1.two types of hyperglycemic emergencies: diabetic ketoacidosis and hyperglycemic hyperosmolar syndrome 2.The patient is pregnant or breastfeeding 3.Patients with hemoglobinopathy

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Compare the ratio of patients with hemoglobin A1C less than or equal to seven percent within 24 weeks after treatment in newly diagnosed type 2 diabetes patients with very high hemoglobin A1C At baseline FBS HbA1C UA UACR SMBG BUN Cr electrolyte CBC CXR EKG 12 leads

Secondary Outcome Measures

Name	Time	Method
Compare the ratio of patients with hemoglobin A1C less than or equal to seven percent within 1 year after treatment in newly diagnosed type 2 diabetes patients with very high hemoglobin A1C At baseline FBS HbA1C UA UACR SMBG BUN Cr electrolyte CBC CXR EKG 12 leads